Orladeyo Approved in United Arab Emirates to Prevent HAE Attacks

Orladeyo Approved in United Arab Emirates to Prevent HAE Attacks

305770

Orladeyo Approved in United Arab Emirates to Prevent HAE Attacks

The United Arab Emirates (UAE) has approved BioCryst Pharmaceuticals’ Orladeyo (berotralstat) for preventing hereditary angioedema (HAE) attacks in patients, 12 and older. “As the first targeted oral, once-daily treatment, Orladeyo provides an important new treatment option for patients and physicians,” Henrik Balle Boysen, executive vice president and chief operating officer of HAE International, a global nonprofit that supports local HAE patient groups and organizations, said in a press release. “While there is still more work…

You must be logged in to read/download the full post.